HDAC inhibitors have been approved for the treatment of T-cell lymphoma (vorinostat, SAHA; belinostat; and romidepsin) or multiple myeloma (panobinostat and LBH589). This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.